Celldex Therapeutics | CLDX - Ebit

Aktienkurs
30.08
Täglich Wechseln
1.54 5.40%
Monatlich
30.67%
Jährlich
51.31%
Q1 Prognose
28.62




Ebit Veränderung Datum
AbbVie USD 5.81B 4.36B 2025-12
Agenus USD 14.4M 19.26M 2025-12
Amgen USD 3.96B 464M 2025-12
Bristol-Myers Squibb USD 3.47B 567M 2025-12
Celldex Therapeutics USD -87.15M 13.54M 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Nektar Therapeutics USD -34.34M 3.68M 2024-09
Northwest Biotherapeutics USD -13.82M 248K 2023-09
Pfizer USD 4.65B 71M 2025-12
Rigel Pharmaceuticals USD 447K 1.52M 2024-06
Roche Holding CHF 9.56B 2.1B 2025-12